LYRClinical•globenewswire•
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Sentiment:Positive (78)
Summary
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusitis (CRS) –
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire